Pathogenesis, natural history, treatment, and prevention of hepatitis C

T. Jake Liang, Barbara Rehermann, Leonard B. Seeff, Jay H. Hoofnagle

Research output: Contribution to journalArticlepeer-review

770 Scopus citations


Approximately 4 million persons in the United States and probably more than 100 million persons worldwide are infected with hepatitis C virus. The virus has the unique ability to cause persistent infection in susceptible hosts after parenteral or percutaneous transmission, and its underlying mechanisms are not well understood. The immunologic correlates of protection and viral clearance and the pathogenesis of liver injury are yet to be defined, but recent studies suggest the importance of cell-mediated immune responses. Although 70% to 80% of infected persons become chronic carriers, most have relatively mild disease with slow progression. However, chronic and progressive hepatitis C carries significant morbidity and mortality and is a major cause of cirrhosis, end-stage liver disease, and liver cancer. Development of an effective hepatitis C virus vaccine is not imminent, but recent advances in technology and basic knowledge of molecular virology and immunology have engendered novel approaches to the fundamental problems encountered in vaccine development. Current therapy for hepatitis C, although effective in some patients, is problematic and still evolving. Advances in modern biology and immunology promise new therapies for this important disease.

Original languageEnglish (US)
Pages (from-to)296-305
Number of pages10
JournalAnnals of Internal Medicine
Issue number4
StatePublished - Feb 15 2000
Externally publishedYes

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Pathogenesis, natural history, treatment, and prevention of hepatitis C'. Together they form a unique fingerprint.

Cite this